Nautilus shares rose 18.4% after earnings. The call’s positive signal was the company’s sharpened focus on proteoforms, with management saying its development roadmap is underway and pointing to demand from the scientific community.
- Nautilus has concentrated resources on proteoforms and says it effectively tripled the people and resources focused on proteoform development.
- The company aims to develop 20 proteoform assays by the middle of 2028.
- Management described its Voyager platform and Iterative Mapping method as designed to read intact protein molecules at scale and resolve their functional states.
- Nautilus cited demand for more proteoforms, sample types, and applications, along with its participation in the SEEDS Consortium, funded up to $51.7 million by ARPA-H.
- The supplied transcript excerpt does not include quarterly financial figures or a detailed financial outlook, limiting assessment of the earnings and near-term business performance.
Community Discussion